[1] TAR-210 results show 90% recurrence-free survival and90% complete response in patients with high-risk and intermediate-risknon-muscle-invasive bladder cancer, respectively. Retrieved May 6, 2024 from https://www.prnewswire.com/news-releases/tar-210-results-show-90-recurrence-free-survival-and-90-complete-response-in-patients-with-high-risk-and-intermediate-risk-nonmuscle-invasive-bladder-cancer-respectively-302135657.html